• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Agenus Inc.

    8/11/25 7:52:57 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AGEN alert in real time by email
    S-8 1 d77473ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on August 11, 2025

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Form S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Agenus Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   06-1562417

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    3 Forbes Road, Lexington, MA 02421

    (Address of principal executive offices, including zip code)

    AGENUS INC. AMENDED AND RESTATED 2019 EQUITY INCENTIVE PLAN

    AGENUS INC. AMENDED AND RESTATED DIRECTORS’ DEFERRED COMPENSATION PLAN

    AGENUS INC. 2019 EMPLOYEE STOCK PURCHASE PLAN

    (Full title of the plan)

    Garo H. Armen, Ph.D.

    Agenus Inc.

    3 Forbes Road

    Lexington, MA 02421

    781-674-4400

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Please send copies of all communications to:

    Zachary Blume

    Ropes & Gray LLP

    Prudential Tower

    800 Boylston Street

    Boston, MA 02199-3600

    (617) 951-7000

     

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☒
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    Explanatory Note

    This Registration Statement on Form S-8 is being filed by Agenus Inc. (the “Registrant”) to register shares of its common stock, $0.01 par value per share (“Common Stock”), solely for use under (i) the Amended and Restated 2019 Equity Incentive Plan (the “2019 Plan”), (ii) the Amended and Restated Directors’ Deferred Compensation Plan (the “DDCP”), and (iii) the 2019 Employee Stock Purchase Plan (the “ESPP”). This filing does not relate to a capital-raising transaction, a public offering, or current issuance of any shares. Any shares covered by this Registration Statement may be delivered only in connection with awards or purchases made under these plans in accordance with their terms.

    At the Registrant’s Annual Meeting of Stockholders held on June 17, 2025, stockholders approved amendments increasing the share reserves under the 2019 Plan, the DDCP, and the ESPP. This Registration Statement covers those additional reserved shares and is an administrative step to permit plan issuances if and when they occur.

    Pursuant to General Instruction E to Form S-8, this registration statement incorporates by reference the contents of the registration statements on Form S-8, File Nos. 333-280462, 333-272888, 333-266790, 333-233100, 333-233097, 333-228271, 333-209074, 333-183067, 333-176609, 333-160088, 333-143807 and 333-106072, filed by the Registrant on June  25, 2024, June 23, 2023, August 11, 2022, August 7, 2019, August  7, 2019, November 8, 2018, January  21, 2016, August 3, 2012, September  1, 2011, June 19, 2009, June  15, 2007 and June 12, 2003, respectively, relating to the 2019 Plan and the DDCP.


    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8

    Exhibits.

     

    Exhibit   

    Description

     4.1    Amended and Restated Certificate of Incorporation of Antigenics Inc. Filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 0-29089) filed on June 10, 2002 and incorporated herein by reference.
     4.2    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Antigenics Inc. Filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 000-29089) filed on June 11, 2007 and incorporated herein by reference.
     4.3    Certificate of Ownership and Merger changing the name of the corporation to Agenus Inc. Filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 0-29089) filed on January 6, 2011 and incorporated herein by reference.
     4.4    Certificate of Second Amendment to the Amended and Restated Certificate of Incorporation of Agenus Inc. Filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 0-29089) filed on September 30, 2011 and incorporated herein by reference.
     4.5    Certificate of Third Amendment to the Amended and Restated Certificate of Incorporation of Agenus Inc. Filed as Exhibit 3.1.4 to the Registrant’s Quarterly Report on Form 10-Q (File No. 0-29089) filed on August 8, 2012 and incorporated herein by reference.
     4.6    Certificate of Fourth Amendment to the Amended and Restated Certificate of Incorporation of Agenus Inc. Filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 0-29089) filed on April 25, 2014 and incorporated herein by reference.
     4.7    Certificate of Fifth Amendment to the Amended and Restated Certificate of Incorporation of Agenus Inc. Filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 0-29089) filed on June 16, 2016 and incorporated herein by reference.
     4.8    Certificate of Sixth Amendment to the Amended and Restated Certificate of Incorporation of Agenus Inc. Filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 0-29089) filed on June 24, 2019 and incorporated herein by reference.
     4.9    Certificate of Seventh Amendment to the Amended and Restated Certificate of Incorporation of Agenus Inc. Filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 0-29089) filed on August 5, 2022 and incorporated herein by reference.
     4.10    Certificate of Eighth Amendment to the Amended and Restated Certificate of Incorporation of Agenus Inc. Filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 0-29089) filed on April 5, 2024 and incorporated herein by reference.
     4.11    Sixth Amended and Restated By-laws of Agenus Inc. Filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 0-29089) filed on March 25, 2022 and incorporated herein by reference.
     4.12    Form of Common Stock Certificate. Filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 0-29089) filed January 6, 2011 and incorporated herein by reference.
     5.1    Opinion of Ropes & Gray LLP dated June 25, 2024. Filed herewith.
    23.1    Consent of Ropes & Gray LLP (included in Opinion filed as Exhibit 5.1).
    23.2    Consent of KPMG LLP, Independent Registered Public Accounting Firm. Filed herewith.
    24.1    Power of Attorney (included on signature page of this registration statement).
    99.1    Agenus Inc. Amended and Restated Directors’ Deferred Compensation Plan. Filed as Appendix B to the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 26, 2018 and incorporated herein by reference.
    99.2    Amendment to Agenus Inc. Amended and Restated Directors’ Deferred Compensation Plan. Filed as Appendix A to the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 28, 2020 and incorporated herein by reference.
    99.3    Amendment to Agenus Inc. Amended and Restated Directors’ Deferred Compensation Plan. Filed as Appendix A to the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 29, 2022 and incorporated herein by reference.


    99.4    Amendment to Agenus Inc. Amended and Restated Directors’ Deferred Compensation Plan. Filed as Appendix B to the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 26, 2024 and incorporated herein by reference.
    99.5    Amendment to Agenus Inc. Amended and Restated Directors’ Deferred Compensation Plan. Filed as Appendix B to the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 30, 2025 and incorporated herein by reference.
    99.6    Agenus Inc. Amended and Restated 2019 Equity Incentive Plan. Filed as Appendix A to the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 30, 2025 and incorporated herein by reference.
    99.7    Agenus Inc. 2019 Employee Stock Purchase Plan. Filed as Exhibit 4.11 to the Registrant’s Registration Statement on Form S-8 (File No. 333-233100) filed on August 7, 2019 and incorporated herein by reference.
    99.8    Amendment to the Agenus Inc. 2019 Employee Stock Purchase Plan. Filed as Appendix B to the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 30, 2021 and incorporated herein by reference.
    99.9    Second Amendment to the Agenus Inc. 2019 Employee Stock Purchase Plan. Filed as Appendix A to the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 28, 2023 and incorporated herein by reference.
    99.10    Third Amendment to the Agenus Inc. 2019 Employee Stock Purchase Plan. Filed as Appendix C to the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 30, 2025 and incorporated herein by reference.
    107    Filing Fee Table. Filed Herewith


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Lexington, Commonwealth of Massachusetts, on this 11 day of August , 2025.

     

    AGENUS INC.
    By:   /s/ Garo H. Armen, Ph.D.
      Garo H. Armen, Ph.D.
      Chief Executive Officer and Chairman of the Board

    POWER OF ATTORNEY

    We, the undersigned officers and directors of Agenus Inc., hereby severally constitute and appoint Garo Armen and Christine M. Klaskin, and each of them singly, our true and lawful attorneys-in-fact, with full power to them in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including any post-effective amendments thereto), and to file the same, with exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact may do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities indicated below on the dates indicated.

     

    SIGNATURE

      

    TITLE

     

    DATE

    /s/ Garo H. Armen, Ph.D.

    Garo H. Armen, Ph.D.

      

    Chief Executive Officer and Chairman of the Board of Directors

    (Principal Executive Officer)

      August 11, 2025

    /s/ Christine M. Klaskin

    Christine M. Klaskin

      

    Vice President, Finance

    (Principal Financial and Accounting Officer)

      August 11, 2025

    /s/ Jennifer Buell, Ph.D

    Jennifer Buell, Ph.D

       Director   August 11, 2025

    /s/ Brian Corvese

    Brian Corvese

       Director   August 11, 2025

    /s/ Tom Harrison

    Tom Harrison

       Director   August 11, 2025

    /s/ Timothy R. Wright

    Timothy R. Wright

       Director   August 11, 2025

    /s/ Susan Hirsch

    Susan Hirsch

       Director   August 11, 2025
    Get the next $AGEN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGEN

    DatePrice TargetRatingAnalyst
    6/4/2025$25.00Neutral → Buy
    H.C. Wainwright
    7/19/2024$35.00 → $8.00Outperform → Neutral
    Robert W. Baird
    7/18/2024Outperform → Mkt Perform
    William Blair
    7/18/2024$9.00Buy → Neutral
    H.C. Wainwright
    6/6/2023$8.00Outperform
    Robert W. Baird
    6/6/2023$60.00 → $80.00Outperform
    Robert W. Baird
    2/28/2023$8.00Buy
    H.C. Wainwright
    9/28/2022$5.00Outperform
    SMBC Nikko
    More analyst ratings

    $AGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Armen Garo H was granted 3,407 shares, increasing direct ownership by 1% to 267,311 units (SEC Form 4)

    4 - AGENUS INC (0001098972) (Issuer)

    8/11/25 4:05:04 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Armen Garo H was granted 2,745 shares, increasing direct ownership by 1% to 263,904 units (SEC Form 4)

    4 - AGENUS INC (0001098972) (Issuer)

    7/28/25 4:06:11 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Armen Garo H was granted 2,317 shares, increasing direct ownership by 0.90% to 261,159 units (SEC Form 4)

    4 - AGENUS INC (0001098972) (Issuer)

    7/15/25 4:05:10 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    SEC Filings

    View All

    SEC Form S-8 filed by Agenus Inc.

    S-8 - AGENUS INC (0001098972) (Filer)

    8/11/25 7:52:57 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Agenus Inc.

    10-Q - AGENUS INC (0001098972) (Filer)

    8/11/25 4:55:50 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AGENUS INC (0001098972) (Filer)

    8/11/25 7:31:27 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Armen Garo H bought $324,050 worth of shares (500,000 units at $0.65) (SEC Form 4)

    4 - AGENUS INC (0001098972) (Issuer)

    2/15/24 6:59:48 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wiinberg Ulf bought $19,000 worth of shares (25,000 units at $0.76), increasing direct ownership by 25% to 124,063 units (SEC Form 4)

    4 - AGENUS INC (0001098972) (Issuer)

    11/17/23 4:22:11 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Agenus upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Agenus from Neutral to Buy and set a new price target of $25.00

    6/4/25 7:30:33 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Agenus from Outperform to Neutral and set a new price target of $8.00 from $35.00 previously

    7/19/24 7:27:15 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus downgraded by William Blair

    William Blair downgraded Agenus from Outperform to Mkt Perform

    7/18/24 1:59:35 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

    Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET. The event will feature presentations from senior management and industry thought leaders, offering insights into transformative developments that could shape the future of cancer treatment. The agenda includes a strategic and financial overview, achievements tied to the Zydus partnership closing, patient needs fueling interest in colorectal cancer (CRC) studies, recent data from the botensilimab (BOT) and balstilimab (BAL) program, and an overview of the Phase 3 BATTMAN study in metastatic CRC—plus highlights of upc

    8/19/25 7:30:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

    Zydus Lifesciences collaboration to close in Q3 with $91M capital infusion to support clinical and regulatory milestones BOT/BAL delivers 42% two-year survival in refractory MSS CRC and consistent activity across multiple solid cancers, to be presented at an oral session at ESMO Regulatory alignment secured for Phase 3 trial initiation, expected to commence in Q4 2025 August 27th virtual stakeholder meeting set for a detailed discussion on progress Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company focused on innovation, today reports financial results for the second quarter of 2025 and highlighted major clinical, regulatory, and operational miles

    8/11/25 7:30:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

    Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2025 financial results before the market opens on Monday, August 11, 2025. Agenus will then host a stakeholder briefing in late August to spotlight key strategic plans, data milestones and provide a comprehensive update on the global botensilimab (BOT) and balstilimab (BAL) development program. About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination app

    7/31/25 7:30:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    Financials

    Live finance-specific insights

    View All

    Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

    Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET. The event will feature presentations from senior management and industry thought leaders, offering insights into transformative developments that could shape the future of cancer treatment. The agenda includes a strategic and financial overview, achievements tied to the Zydus partnership closing, patient needs fueling interest in colorectal cancer (CRC) studies, recent data from the botensilimab (BOT) and balstilimab (BAL) program, and an overview of the Phase 3 BATTMAN study in metastatic CRC—plus highlights of upc

    8/19/25 7:30:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

    Zydus Lifesciences collaboration to close in Q3 with $91M capital infusion to support clinical and regulatory milestones BOT/BAL delivers 42% two-year survival in refractory MSS CRC and consistent activity across multiple solid cancers, to be presented at an oral session at ESMO Regulatory alignment secured for Phase 3 trial initiation, expected to commence in Q4 2025 August 27th virtual stakeholder meeting set for a detailed discussion on progress Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company focused on innovation, today reports financial results for the second quarter of 2025 and highlighted major clinical, regulatory, and operational miles

    8/11/25 7:30:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

    $75M upfront payment to Agenus for the transfer of manufacturing assets $50M of contingent payments to Agenus Exclusive license for BOT/BAL in India and Sri Lanka $16M equity investment at $7.50 per share Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidiaries/affiliates, hereafter referred to as "Zydus," designed to accelerate clinical development, scale global manufacturing, and expand patient access to botensilimab and balstilimab (BOT/BAL). The strategic collaboration includes an exchange of Agenus' state-of-the-art biologics

    6/3/25 7:00:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    Leadership Updates

    Live Leadership Updates

    View All

    Agenus Announces Appointment of Tom Harrison to Board of Directors

    Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline Agenus Inc. (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising. Tom Harrison's Background Highlights: Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's largest group of marketing services companies, overseeing an unparalleled range of services including public relations, crisis management, bran

    8/8/24 7:00:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors

    Strategic leadership to drive next phase of growth for the company Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensures a seamless integration of strategic insights across both organizations, enhancing our collaborative efforts to innovate and deliver breakthrough cancer therapies.

    6/17/24 7:00:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus Expands Executive Leadership Team

    Robin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer Homa Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer Stephanie Fagan Appointed Chief Communications Officer Immuno-oncology leader, Agenus Inc. ("Agenus") (NASDAQ:AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company's next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics. Chief Commercial Officer, Robin Ta

    7/20/23 7:30:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agenus Inc.

    SC 13G/A - AGENUS INC (0001098972) (Subject)

    11/14/24 7:58:18 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Agenus Inc.

    SC 13G/A - AGENUS INC (0001098972) (Subject)

    11/14/24 9:21:26 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Agenus Inc. (Amendment)

    SC 13G/A - AGENUS INC (0001098972) (Subject)

    6/10/24 12:15:17 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care